Ascend Advanced Therapies vs Charles River Laboratories: CDMO Comparison
How does Ascend Advanced Therapies compare to Charles River Laboratories for AAV manufacturing?
Side-by-side comparison of Ascend Advanced Therapies and Charles River Laboratories on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Charles River Laboratories has more FDA inspections on record (9 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Charles River Laboratories has materially broader EMA GMP coverage (9 active certificates vs 1) — stronger EU footprint.
- Charles River Laboratories maintains 2 MHRA / UK GMP certificates; Ascend Advanced Therapies does not.
On a 13-modality CDMO landscape, both Ascend Advanced Therapies and Charles River Laboratories qualify as AAV manufacturers; Charles River Laboratories carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Ascend Advanced Therapies and Charles River Laboratories qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Ascend Advanced Therapies vs Charles River Laboratories
How does Ascend Advanced Therapies compare to Charles River Laboratories for AAV manufacturing?
On CDMO Signal's composite Signal Score, Ascend Advanced Therapies is 78/100 and Charles River Laboratories is 86/100; Ascend Advanced Therapies has 0 FDA inspections on record vs 9 for Charles River Laboratories; European coverage is 1 active EMA+MHRA certificate for Ascend Advanced Therapies vs 11 for Charles River Laboratories. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Ascend Advanced Therapies or Charles River Laboratories?
Both Ascend Advanced Therapies and Charles River Laboratories maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Ascend Advanced Therapies has 0 FDA inspections on record; Charles River Laboratories has 9.
How do Ascend Advanced Therapies and Charles River Laboratories compare on European GMP coverage?
Ascend Advanced Therapies holds 1 active EMA GMP certificate and 0 MHRA / UK certificates. Charles River Laboratories holds 9 active EMA GMP certificates and 2 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for AAV manufacturing — Ascend Advanced Therapies or Charles River Laboratories?
Both Ascend Advanced Therapies and Charles River Laboratories are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Ascend Advanced Therapies carries a Signal Score of 78/100 and Charles River Laboratories carries 86/100 — a small lead for Charles River Laboratories. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →